Beijing Wandong Medical Technology (600055)
- 10.55
- -0.48-4.35%
Beijing Wandong Medical Technology (600055) News
Wandong Medical: Wandong Medical\'s 2026 Semi-Annual Performance Forecast
Wandong Medical (600055.SH): Has repurchased 0.64% of the company's shares.
Gelonghui, June 30 — Wandong Medical (SHA: 600055) announced that as of June 30, 2026, the company has completed its share repurchase program. A total of 4,499,800 shares were repurchased, representing approximately 0.64% of the company's total share capital. The highest repurchase price was RMB 17.99 per share, the lowest was RMB 10.31 per share, and the average repurchase price was RMB 13.33 per share, with a total amount of RMB 59,989,800 (excluding transaction fees) utilized for the repurchases.
Authoritative journals have affirmed that helium-free technology represents the ultimate direction for magnetic resonance—domestically produced high-end medical equipment is accelerating toward self-reliance and supply chain security.
All-solid-state conduction cooling technology without liquid helium has become the ultimate direction of industry development.
Wandong Medical (600055.SH): Has cumulatively repurchased 1.8027 million shares.
Gelonghui, June 1 — Wandong Medical (SHA: 600055) announced that, as of the end of May 2026, the company had cumulatively repurchased 1.8027 million shares through centralized bidding transactions. The repurchased shares accounted for 0.2564% of the company's total share capital, with a highest purchase price of RMB 17.99 per share and a lowest price of RMB 15.71 per share. The total amount paid was RMB 29.9928 million (excluding transaction fees).
Express News | Wandong Medical: Obtained the Medical Device Registration Certificate for a Medical Angiography X-ray System
Wandong Medical (600055): Short-term performance pressure expected to gradually improve by 2026.
The core perspective is that the company's performance in the 25th year faced short-term pressures, primarily due to factors such as the timing of revenue recognition, the impact of centralized procurement, and significant expense investments. In the domestic public hospital market, the number of bids won by the company quadrupled in the 25th year, but there was a certain lag in revenue recognition.
AVIC Securities: Significant AI healthcare collaborations emerge, with application scenarios expanding in depth.
AI is transitioning from a 'technical assistance' role to become the core driving force behind the 'value reconfiguration' and 'efficiency revolution' in the healthcare industry, with its commercial value permeating comprehensively from the research and development end to the clinical end, payment end, and patient end.
Wandong Medical (600055.SH) reported its first-quarter performance, with a net loss attributable to shareholders of 15.93 million yuan.
Wandong Medical (600055.SH) disclosed its first-quarter report for 2026. During the reporting period, the company achieved revenue of 407 million yuan, representing a year-on-year increase of 8.92%. The net profit attributable to shareholders recorded a loss of 15.93 million yuan, turning from profit to loss compared with the same period last year. The non-recurring net profit also turned from profit to loss, amounting to a loss of 18.03 million yuan. The basic earnings per share were -0.023 yuan.
Wandong Medical 2026 First Quarter Report
Wandong Medical (600055.SH) reported a net loss of 15.934 million yuan in the first quarter.
Gelonghui reported on April 24 that Wandong Medical (600055.SH) released its Q1 2026 earnings report, showing the company achieved revenue of 407 million yuan in the first quarter, representing a year-on-year increase of 8.92%. The net profit attributable to shareholders was -15.934 million yuan, and the non-recurring net profit attributable to shareholders was -18.0339 million yuan.
Express News | Wandong Medical, a subsidiary of Midea Group, has released the industry's first rare earth suspension DSA-Genesis X5.
Wandong Medical (600055.SH): Cumulative repurchase of 1.8027 million company shares
Gelonghui, April 1st: Wandong Medical (600055.SH) announced that as of the end of March 2026, the company had cumulatively repurchased 1.8027 million shares through centralized bidding. The repurchased shares accounted for 0.2564% of the company's total share capital. The highest purchase price was RMB 17.99 per share, and the lowest was RMB 15.71 per share. The total amount paid was RMB 29,992,822.08 (excluding transaction fees).
Wandong Medical posts its first annual loss; the 'Midea Group' healthcare strategy undergoes changes as Executive President Wang Jianguo takes over leadership.
After Midea Group took over, it provided significant support to Wandong Medical in terms of resources and technology.
Wandong Medical: Wandong Medical 2025 Annual Report
Wandong Medical: Summary of Wandong Medical\'s 2025 Annual Report
Wandong Medical 2025 Annual Report
Wandong Medical 2025 Annual Report Summary
Wandong Medical (600055.SH) reported its 2025 financial results, posting a net loss of 228 million yuan after turning from profit to loss.
Wandong Medical (600055.SH) released its annual report for 2025. During the reporting period, the company achieved operating revenue of 1.347 billion yuan, representing a year-on-year decrease of 11.64%. The net loss attributable to shareholders of the listed company amounted to 228 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 245 million yuan. The basic loss per share was 0.324 yuan.
Wandong Medical (600055.SH): Lian Shijun, a director representing the employees, has resigned.
Gelonghui, March 9th - Wandong Medical (600055.SH) announced that the company's board of directors recently received a written resignation report from Lian Shijun, a member of the board representing employees. Mr. Lian Shijun resigned from his position as an employee director due to personal reasons and will no longer hold any position in the company after leaving. After deliberation at the company’s employee representative conference, Ms. Chi Shuang was elected as a member of the tenth board of directors representing employees. Her term will be consistent with the tenure of the tenth board of directors.
AVIC Securities: Acceleration in AI-Driven Drug Discovery Demonstrates International Competitiveness of Domestic Large Medical Models
From the perspective of scenario-based needs, the investment logic of AI in healthcare primarily lies in addressing industry pain points.